1. DEFINITION AND CLASSIFICATION
- Definition: A fatal, progressive neurodegenerative Lysosomal Storage Disorder (LSD) caused by deficiency of the enzyme Beta-Hexosaminidase A.
- Classification:
- Infantile (Classic): Onset <6 months, rapid progression, death by 4-5 years.
- Juvenile: Onset 2-10 years, ataxia, progressive cognitive decline.
- Adult (Late-Onset): Onset in adolescence/adulthood, motor neuron disease-like presentation, psychosis.
2. ETIOLOGY AND GENETICS
- Inheritance: Autosomal Recessive.
- Gene: HEXA gene on chromosome 15q23.
- Enzyme Defect: Deficiency of Beta-Hexosaminidase A (specifically the alpha-subunit).
- Note: Deficiency of Beta-Hexosaminidase A & B occurs in Sandhoff Disease (beta-subunit defect).
- Epidemiology: High carrier frequency (1 in 27) in Ashkenazi Jewish population. Also increased in French Canadians and Cajuns.
- Pathophysiology:
- Inability to degrade GM2 ganglioside.
- Accumulation of GM2 ganglioside in neuronal lysosomes causes ballooning of neurons, cellular dysfunction, and apoptosis.
- Onset: Infants appear normal until 3-5 months of age.
- Early Signs:
- Hyperacusis: Exaggerated startle response to sharp sounds (often the earliest and most characteristic sign).
- Poor visual fixation/tracking.
- Hypotonia and listlessness (“Approach to a floppy infant”).
- Loss of previously acquired motor milestones.
- Ophthalmologic:
- Cherry-Red Spot: Present in >90% of cases. Caused by lipid-laden whitish ganglion cells surrounding the normal red fovea centralis.
- Optic atrophy and eventual blindness.
- Neurologic Progression:
- Macrocephaly: Develops after 12-18 months due to reactive cerebral gliosis (brain overgrowth), not hydrocephalus.
- Spasticity, hyperreflexia, and extensor plantar responses replace initial hypotonia.
- Seizures: Tonic-clonic or myoclonic, often refractory to treatment.
- Decerebrate posturing.
- Systemic: NO Hepatosplenomegaly (Important distinction from Niemann-Pick and Sandhoff Disease).
4. INVESTIGATIONS
- Enzyme Assay (Gold Standard):
- Demonstration of absent or markedly reduced Beta-Hexosaminidase A activity in serum, leukocytes, or fibroblasts.
- Total hexosaminidase activity may be normal or elevated (due to compensatory increase in Hex B).
- Molecular Genetics: HEXA gene sequencing (confirms diagnosis and identifies specific mutations).
- Imaging (MRI Brain):
- Thalamic hyperdensity on CT (suggestive early sign).
- T2 hyperintensity in basal ganglia/white matter.
- Progressive cerebral atrophy in late stages.
5. MANAGEMENT
- Curative: None available currently.
- Supportive Care:
- Nutrition: Nasogastric or gastrostomy tube feeding for dysphagia/aspiration risk.
- Seizure Control: Antiepileptics (often difficult to control).
- Respiratory: Suctioning, chest physiotherapy for secretion management.
- Prevention:
- Carrier Screening: Enzyme assay or DNA testing recommended for high-risk populations (Ashkenazi Jews).
- Prenatal Diagnosis: CVS or amniocentesis for enzyme analysis.
6. PROGNOSIS
- Infantile Form: Invariably fatal. Death typically occurs by 2 to 4 years of age, usually due to bronchopneumonia.
